Klabenkova Kristina, Zakhryamina Alyona, Burakova Ekaterina, Bizyaev Sergei, Fokina Alesya, Stetsenko Dmitry
Department of Physics, Novosibirsk State University, 2 Pirogov Str., Novosibirsk 630090, Russia.
Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, 10 Lavrentiev Ave., Novosibirsk 630090, Russia.
Int J Mol Sci. 2024 Dec 31;26(1):300. doi: 10.3390/ijms26010300.
Nowadays, nucleic acid derivatives capable of modulating gene expression at the RNA level have gained widespread recognition as promising therapeutic agents. A suitable degree of biological stability of oligonucleotide therapeutics is required for in vivo application; this can be most expeditiously achieved by the chemical modification of the internucleotidic phosphate group, which may also affect their cellular uptake, tissue distribution and pharmacokinetics. Our group has previously developed a strategy for the chemical modification of the phosphate group via the Staudinger reaction on a solid phase of the intermediate dinucleoside phosphite triester and a range of, preferably, electron deficient organic azides such as sulfonyl azides during automated solid-phase DNA synthesis according to the conventional β-cyanoethyl phosphoramidite scheme. Polyfluoro compounds are characterized by unique properties that have prompted their extensive application both in industry and in scientific research. We report herein the synthesis and isolation of novel oligodeoxyribonucleotides incorporating internucleotidic perfluoro-1-octanesulfonyl phosphoramidate or 2,2,2-trifluoroethanesulfonyl phosphoramidate groups. In addition, novel oligonucleotide derivatives with fluorinated zwitterionic phosphate mimics were synthesized by a tandem methodology, which involved () the introduction of a carboxylic ester group at the internucleotidic position via the Staudinger reaction with methyl 2,2-difluoro-3-azidosulfonylacetate; and () treatment with an aliphatic diamine, e.g., 1,1-dimethylethylenediamine or 1,3-diaminopropane. It was further shown that the polyfluoro oligonucleotides obtained were able to form complementary duplexes with either DNA or RNA, which were not significantly differing in stability from the natural counterparts. Long-chain perfluoroalkyl oligonucleotides were taken up into cultured human cells in the absence of a transfection agent. It may be concluded that the polyfluoro oligonucleotides described here can represent a useful platform for designing oligonucleotide therapeutics.
如今,能够在RNA水平上调节基因表达的核酸衍生物作为有前景的治疗剂已获得广泛认可。寡核苷酸疗法在体内应用需要适度的生物稳定性;这可以通过对核苷酸间磷酸基团进行化学修饰最迅速地实现,这种修饰也可能影响其细胞摄取、组织分布和药代动力学。我们小组先前已经开发了一种策略,即在根据传统的β-氰基乙基亚磷酰胺方案进行自动固相DNA合成过程中,通过在中间亚磷酸二酯核苷固相上的施陶丁格反应,使用一系列,优选缺电子有机叠氮化物如磺酰叠氮化物,对磷酸基团进行化学修饰。多氟化合物具有独特的性质,这促使它们在工业和科研中得到广泛应用。我们在此报告了新型寡脱氧核糖核苷酸的合成与分离,这些寡脱氧核糖核苷酸含有核苷酸间全氟-1-辛烷磺酰胺基磷酸酯或2,2,2-三氟乙烷磺酰胺基磷酸酯基团。此外,通过串联方法合成了具有氟化两性离子磷酸模拟物的新型寡核苷酸衍生物,该方法包括:(i)通过与2,2-二氟-3-叠氮基磺酰基乙酸甲酯的施陶丁格反应在核苷酸间位置引入羧酸酯基团;(ii)用脂肪族二胺如1,1-二甲基乙二胺或1,3-二氨基丙烷处理。进一步表明,所获得的多氟寡核苷酸能够与DNA或RNA形成互补双链体,其稳定性与天然对应物没有显著差异。在没有转染剂的情况下,长链全氟烷基寡核苷酸被培养的人细胞摄取。可以得出结论,本文所述的多氟寡核苷酸可以代表设计寡核苷酸疗法的有用平台。